Faes Farma Stock

Faes Farma Net Debt

The Net Debt of Faes Farma (FAE.MC) as of Aug 8, 2026 is 428.52 M EUR. In the previous year, Net Debt was -51.59 M EUR — a change of -930.62% (higher).

Net Debt

428.52 MEUR

YoY

-930.62%

Last updated:

Net Debt of Faes Farma is 2026 428.52 M EUR. Net Debt of Faes Farma was 2025 -51.59 M EUR. It decreases by -930.62% higher compared to the previous year.
Access this data via the Eulerpool API

Faes Farma Stock analysis

What does Faes Farma do? The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Faes Farma stock

Net Debt of Faes Farma is 428.52 M EUR in 2026.

Net Debt of Faes Farma changed from -51.59 M EUR to 428.52 M EUR, representing a -930.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Faes Farma since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Faes Farma historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Faes Farma

All Key Metrics — Faes Farma